A study in mice reveals that stem cell transplants, currently in clinical trials, may not actually require the cells.

A new tool helps stem cells integrate with host neural circuitry after implantation in mice.

The California Institute for Regenerative Medicine has been funding research since it formed in 2004, giving out nearly $3 billion in grants to date.

The cells, derived from induced pluripotent stem cells, are in testing as an immunotherapy for cancer patients with solid tumors.

Age-related macular degeneration patients who received injections of retinal cells derived from donors’ induced pluripotent stem cells have maintained their level of eyesight for a year.

The treatment will be tested in a handful of patients who suffered nerve damage in sports or traffic accidents.

Critics say the misleading term actually refers to a heterogeneous population of cells, including possible tissue-specific progenitor cells and nonstem cells all lumped together.

Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.

The stem cell–derived transplants were stable for 24 months and led to wide-ranging behavioral improvements in the monkeys.